Repare Therapeutics (RPTX) Stock Price
Repare Therapeutics Price
Over the last 4 years Repare Therapeutics grew revenue by 346.1% annually, reaching 53.48 M USD. For Repare Therapeutics, the net margin of -158.4% is up versus -39,568.1% a few years ago. The consensus 12-month price target for Repare Therapeutics is 3.06 USD, about 15.5% above where the stock trades today. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 75% above its 52-week low.
Repare Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Repare Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Repare Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Repare Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Repare Therapeutics Price |
|---|---|
| 1/27/2026 | 2.65 USD |
| 1/26/2026 | 2.63 USD |
| 1/23/2026 | 2.62 USD |
| 1/22/2026 | 2.59 USD |
| 1/21/2026 | 2.59 USD |
| 1/20/2026 | 2.58 USD |
| 1/16/2026 | 2.58 USD |
| 1/15/2026 | 2.57 USD |
| 1/14/2026 | 2.60 USD |
| 1/13/2026 | 2.59 USD |
| 1/12/2026 | 2.57 USD |
| 1/9/2026 | 2.54 USD |
| 1/8/2026 | 2.53 USD |
| 1/7/2026 | 2.56 USD |
| 1/6/2026 | 2.57 USD |
| 1/5/2026 | 2.57 USD |
| 1/2/2026 | 2.57 USD |
| 12/31/2025 | 2.60 USD |
| 12/30/2025 | 2.58 USD |
| 12/29/2025 | 2.56 USD |
| 12/26/2025 | 2.57 USD |
| 12/24/2025 | 2.55 USD |
| 12/23/2025 | 2.17 USD |
| 12/22/2025 | 2.22 USD |
| 12/19/2025 | 2.14 USD |
| 12/18/2025 | 2.15 USD |
| 12/17/2025 | 2.19 USD |
| 12/16/2025 | 2.23 USD |
| 12/15/2025 | 2.20 USD |
| 12/12/2025 | 2.14 USD |
| 12/11/2025 | 2.14 USD |
| 12/10/2025 | 2.15 USD |
| 12/9/2025 | 2.16 USD |
| 12/8/2025 | 2.15 USD |
| 12/5/2025 | 2.22 USD |
| 12/4/2025 | 2.23 USD |
| 12/3/2025 | 2.17 USD |
| 12/2/2025 | 2.13 USD |
| 12/1/2025 | 2.13 USD |
| 11/28/2025 | 2.18 USD |
| 11/26/2025 | 2.21 USD |
| 11/25/2025 | 2.12 USD |
| 11/24/2025 | 2.12 USD |
| 11/21/2025 | 2.11 USD |
| 11/20/2025 | 2.10 USD |
| 11/19/2025 | 2.15 USD |
| 11/18/2025 | 2.23 USD |
| 11/17/2025 | 2.18 USD |
| 11/14/2025 | 1.65 USD |
| 11/13/2025 | 1.69 USD |
| 11/12/2025 | 1.72 USD |
| 11/11/2025 | 1.73 USD |
| 11/10/2025 | 1.72 USD |
| 11/7/2025 | 1.69 USD |
| 11/6/2025 | 1.69 USD |
| 11/5/2025 | 1.73 USD |
| 11/4/2025 | 1.78 USD |
| 11/3/2025 | 1.84 USD |
| 10/31/2025 | 1.84 USD |
| 10/30/2025 | 1.77 USD |
| 10/29/2025 | 1.78 USD |
| 10/28/2025 | 1.79 USD |
| 10/27/2025 | 1.87 USD |
| 10/23/2025 | 1.93 USD |
| 10/22/2025 | 1.91 USD |
| 10/21/2025 | 1.88 USD |
| 10/20/2025 | 1.88 USD |
| 10/16/2025 | 1.86 USD |
| 10/15/2025 | 1.90 USD |
| 10/14/2025 | 1.87 USD |
| 10/13/2025 | 1.82 USD |
| 10/9/2025 | 1.83 USD |
| 10/8/2025 | 1.82 USD |
| 10/7/2025 | 1.82 USD |
| 10/6/2025 | 1.84 USD |
| 10/2/2025 | 1.84 USD |
| 10/1/2025 | 1.79 USD |
| 9/30/2025 | 1.76 USD |
| 9/29/2025 | 1.74 USD |
| 9/25/2025 | 1.67 USD |
| 9/24/2025 | 1.73 USD |
| 9/23/2025 | 1.71 USD |
| 9/22/2025 | 1.72 USD |
| 9/18/2025 | 1.77 USD |
| 9/17/2025 | 1.74 USD |
| 9/16/2025 | 1.74 USD |
| 9/15/2025 | 1.77 USD |
| 9/11/2025 | 1.81 USD |
| 9/10/2025 | 1.76 USD |
| 9/9/2025 | 1.73 USD |
| 9/8/2025 | 1.71 USD |
| 9/4/2025 | 1.69 USD |
| 9/3/2025 | 1.72 USD |
| 9/2/2025 | 1.70 USD |
| 8/28/2025 | 1.66 USD |
| 8/27/2025 | 1.65 USD |
| 8/26/2025 | 1.61 USD |
| 8/25/2025 | 1.58 USD |
| 8/21/2025 | 1.55 USD |
| 8/20/2025 | 1.54 USD |
| 8/19/2025 | 1.53 USD |
| 8/18/2025 | 1.54 USD |
| 8/14/2025 | 1.56 USD |
| 8/13/2025 | 1.59 USD |
| 8/12/2025 | 1.56 USD |
| 8/11/2025 | 1.54 USD |
| 8/7/2025 | 1.52 USD |
| 8/6/2025 | 1.53 USD |
| 8/5/2025 | 1.54 USD |
| 8/4/2025 | 1.52 USD |
| 7/31/2025 | 1.51 USD |
| 7/30/2025 | 1.51 USD |
| 7/29/2025 | 1.53 USD |
| 7/28/2025 | 1.58 USD |
Repare Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Repare Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | 7.00 | 131.00 | 51.00 | 53.00 | 7.00 | 10.00 |
| – | – | – | – | – | 1,771.43 | -61.07 | 3.92 | -86.79 | 42.86 |
| – | – | – | – | -1,142.86 | 11.45 | 72.55 | 75.47 | 75.47 | 75.47 |
| 40.00 | 40.00 | 40.00 | -38.00 | -80.00 | 15.00 | 37.00 | 40.00 | 5.28 | 7.55 |
| -6.00 | -12.00 | -25.00 | -54.00 | -108.00 | -19.00 | -116.00 | -93.00 | -99.00 | -32.00 |
| – | – | – | – | -1,542.86 | -14.50 | -227.45 | -175.47 | -1,414.29 | -320.00 |
| -7.00 | -14.00 | -27.00 | -53.00 | -106.00 | -29.00 | -93.00 | -84.00 | -90.00 | -31.00 |
| – | 100.00 | 92.86 | 96.30 | 100.00 | -72.64 | 220.69 | -9.68 | 7.14 | -65.56 |
| 42.41 | 42.41 | 23.19 | 36.78 | 40.17 | 42.04 | 42.14 | 42.41 | 42.41 | 42.41 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Repare Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Repare Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Repare Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Repare Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Repare Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Repare Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Repare Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Repare Therapeutics business model & stock analysis
Repare Therapeutics SWOT Analysis
Strengths
Repare Therapeutics Inc possesses several strengths that contribute to its competitive advantage in the market:
- Strong Intellectual Property Portfolio: Repare Therapeutics has a robust portfolio of intellectual property rights, including patents and trade secrets, which protect its innovative products and technologies.
- Experienced Management Team: The company is led by a highly skilled management team with extensive experience in the biotechnology industry. Their expertise provides strategic direction and effective decision-making.
- Cutting-Edge Research and Development: Repare Therapeutics invests significantly in research and development to discover and develop novel therapies. This commitment to innovation enables the company to stay ahead of competitors.
- Partnerships and Collaborations: The company has established strategic partnerships with leading pharmaceutical companies, allowing for collaborative research projects and potential access to additional resources and markets.
- Strong Financial Position: Repare Therapeutics enjoys a solid financial backing, allowing it to fund its operations, research initiatives, and clinical trials without significant financial constraints.
Weaknesses
While Repare Therapeutics has many strengths, it also faces certain weaknesses that may hinder its growth and success:
- Dependence on Limited Product Portfolio: The company's success heavily relies on the performance and market acceptance of its limited product portfolio. Failure of these products could adversely impact its future prospects.
- Early Stage of Drug Development: Most of Repare Therapeutics' products are in the early stages of development, making them subject to various risks, such as regulatory hurdles, clinical trial failures, and unpredictable market dynamics.
- Reliance on External Funding: As a research-intensive company, Repare Therapeutics heavily relies on external funding sources, such as venture capital investments and collaborations. Economic downturns or limited availability of funding could pose a challenge.
Opportunities
Repare Therapeutics can capitalize on several opportunities to fuel its growth and gain a competitive edge:
- Market Expansion: The growing demand for innovative therapies presents an opportunity for Repare Therapeutics to expand its market reach and target a wider patient population.
- Advancements in Technology: Technological advancements, such as gene editing and precision medicine, provide opportunities for Repare Therapeutics to develop breakthrough therapies with improved efficacy and safety profiles.
- Emerging Markets: Repare Therapeutics can explore partnerships and market entry strategies to tap into emerging markets, where there may be high unmet medical needs and faster approval processes.
Threats
Despite its strengths and opportunities, Repare Therapeutics must also navigate potential threats that could impact its growth and profitability:
- Regulatory Challenges: The biopharmaceutical industry is heavily regulated, and Repare Therapeutics may face challenges in obtaining regulatory approvals for its products. Delays in approvals or changes in regulations could hinder the company's progress.
- Intense Competition: The biotechnology sector is highly competitive, with numerous established players and emerging startups. Repare Therapeutics must stay ahead of competitors in terms of research, product development, and commercialization efforts.
- Market Volatility: Fluctuations in the global financial markets, changes in healthcare policies, and shifts in consumer preferences can all impact the market demand for Repare Therapeutics' products and its ability to generate revenue.
- Intellectual Property Risks: Intellectual property infringement by competitors or challenges to the company's patents and trade secrets could disrupt Repare Therapeutics' business and limit its ability to protect its innovations.
Repare Therapeutics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Repare Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Repare Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Repare Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Repare Therapeutics forecasts and price targets in July 2026
Analyst Price Targets 2026| Δ MOM Price Target | 0.00 % |
| Buy | 75.00 % (6) |
| Hold | 25.00 % (2) |
| Sell | 0.00 % (0) |
| 12M Price Target | 3.06 |
| Last Price | 2.65 |
| Currency | USD |
| 12M Return Potential | 15.47 % |
| LTM Return | 0 % |
Repare Therapeutics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 11/14/2025 | -0.12USD | 7.65 MUSD | 2025 Q3 |
| 5/7/2024 | -0.85USD | 6.69 MUSD | 2024 Q1 |
| 2/26/2024 | -0.59USD | 17.51 MUSD | 2023 Q4 |
| 11/7/2023 | -0.84USD | 3.17 MUSD | 2023 Q3 |
| 8/2/2023 | -0.74USD | 3.14 MUSD | 2023 Q2 |
| 5/3/2023 | -0.62USD | 16.84 MUSD | 2023 Q1 |
| 2/27/2023 | -0.92USD | 1.60 MUSD | 2022 Q4 |
| 11/9/2022 | -0.91USD | 1.60 MUSD | 2022 Q3 |
| 8/4/2022 | -0.86USD | 1.98 MUSD | 2022 Q2 |
| 5/5/2022 | -0.87USD | 2.39 MUSD | 2022 Q1 |
Repare Therapeutics shareholder structure
| % | Name |
|---|---|
19.28818% | |
7.72851% | |
6.90312% | |
6.51344% | |
6.34475% | |
6.24423% |
Repare Therapeutics Executives and Management Board
Mr. Lloyd Segal
(58)President, Chief Executive Officer, Director · since 2016
Dr. Maria Koehler
(66)Executive Vice President, Chief Medical Officer
Dr. Michael Zinda
(51)Executive Vice President, Chief Scientific Officer · since 2019
Mr. Steve Forte
(43)Chief Financial Officer, Executive Vice President
Mr. Thomas Civik
(53)Independent Chairman of the Board
Repare Therapeutics Supply Chain
Repare Therapeutics Supply Chain
Correlation: how closely stock prices move together
| # | Name | 1M | 3M | 6M | 1Y | 2Y | Trend |
|---|---|---|---|---|---|---|---|
| 1 | 0.12 | 0.79 | 0.95 | — | — | ||
| 2 | 0.23 | -0.74 | -0.83 | -0.29 | — | ||
| 3 | -0.22 | -0.69 | -0.79 | -0.79 | — |
Frequently asked questions about Repare Therapeutics
Repare Therapeutics Inc. is a pharmaceutical company that focuses on developing precision oncology drugs. Their business model revolves around utilizing synthetic lethality, a cutting-edge approach to target specific genetic vulnerabilities in cancer cells. By exploiting the DNA repair pathways unique to cancer cells, Repare aims to develop novel therapies with enhanced efficacy and limited side effects. Their research and development efforts are driven by a robust pipeline of small molecule candidates, aiming to address the unmet medical needs of cancer patients. Repare Therapeutics Inc. is committed to revolutionizing cancer treatment through innovative precision medicine solutions.
Repare Therapeutics stock
Repare Therapeutics Peer Group
Repare Therapeutics Ticker
Repare Therapeutics FIGI
All fundamentals and in-depth analysis of Repare Therapeutics
Our stock analysis for Repare Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.